SVSanjay Vikrant

Sanjay Vikrant

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sanjay Vikrant has a total of 257 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Bilateral intrarenal aneurysms in anti-GBM/ANCA overlap syndrome

    by Ajay Jaryal, Karamvir Chandel, Alok Sharma, Sanjay Vikrant

  • Open Access

    Nephrology in Himachal Pradesh

    by Sanjay Vikrant, Ajay Jaryal

    Nephrology in Himachal Pradesh began at the Indira Gandhi Medical College, Shimla, which, till recently, was the only tertiary care hospital providing nephrology services to the state. The first hemodialysis in the state was performed in 1977. The development of renal services has picked up in the last two decades. The National Pradhan Mantri National Dialysis Program has led to the expansion of dialysis services. Challenges include a need for a nephrology workforce. Active nephrology training programs and kidney transplants are needed to improve renal care and services. Further, renal registries in the state can improve the quality of the workforce and service delivery.

  • Anti-glomerular basement membrane disease: Treatment outcome of cyclophosphamide vs. rituximab induction therapy regimen

    by Ajay Jaryal, Sanjay Vikrant

    Aim: To study the clinical profile of anti-glomerular basement membrane (anti-GBM) disease and its outcome with two different treatment regimens comprising either cyclophosphamide (CYC) or rituximab (RTX). Materials and methods: A r etrospective analysis of anti-GBM crescentic glomerulonephritis patients admitted to our hospital over 5 years. Results: 14 patients were diagnosed with anti-GBM crescentic glomerulonephritis. The mean duration of symptoms was 3.6 +/- 1.9 weeks. All patients presented with rapidly progressive glomerulonephritis (RPGN). Five (35.7%) patients had concomitant urinary tract infection (UTI), 2 (14.3% had underlying type 2 diabetes mellitus, 5 (35.7%) patients also had positive anti-neutrophil cytoplasmic antibodies (ANCA), and 9 (64.3%) were dialysis-dependent at presentation. Four (28.6%) patients developed diffuse alveolar hemorrhage (DAH). All patients received baseline corticosteroids, and 7 (50%) patients also received plasmapheresis. Nine (64.3%) patients were treated with CYC, and 3 (21.4%) patients received RTX. In the CYC arm, 2 (28.6%) patients died, 3 had end-stage kidney disease (ESKD) at 3 months, and 2 had chronic kidney disease (CKD) stage III at 3 months of follow-up. Two patients were lost to followup. In the RTX arm, all 3 patients survived with no incidence of DAH, 1 patient each had ESKD and CKD stage III, and 1 dialysisdependent patient achieved normal kidney function at the end of 3 months. Conclusion: Most patients presented late with dialysisdependent renal failure, and many had concomitant UTI. Concomitant infection causes diagnostic confusion with RPGN and DAH, which delays diagnosis and treatment. RTX as an alternative to CYC in addition to baseline corticosteroids and/or plasmapheresis and is associated with favorable outcomes.


  • Epidemiology and outcomes of dialysis requiring acute kidney injury: A single‐center study

    by Ajay Jaryal, Sanjay Vikrant, Dalip Gupta

    Objectives: Acute kidney injury (AKI) is a common diagnosis in hospitalized patients. Dialysis requiring AKI (AKI‐D) is associated with adverse outcomes. This study aims to know the clinical profile and short‐term outcomes at 3 months, in patients with AKI‐D, at our center.Methods: A prospective observational study was done of all the patients admitted with AKI‐D for 2 years, from July 2018 to June 2020. We recorded clinical parameters at baseline and postdischarge follow‐up at 3 months.Results: One hundred twenty‐eight patients had AKI‐D over 2 years. Then, 116 (90.6%) patients had community‐acquired AKI (CAAKI), and 12 (9.4%) patients had hospital‐acquired AKI. The underlying causes of AKI‐D were: toxins in 48 (37.5%), sepsis in 31 (24.2%), acute kidney disease in 15 (11.7%), acute gastroenteritis (AGE) in 9 (7%), and cardiogenic shock in 7 (5.5%) patients. The mean values of intact parathyroid hormone (available in 32% of patients) were 268 pg/mL. Intermittent hemodialysis was the commonest mode of dialysis (85.2%). A kidney biopsy was done in 23 (18%) patients. The most common diagnosis on kidney biopsy was glomerulonephritis (GN) in 12 patients (crescentic GN‐9 and IgA nephropathy‐3), followed by acute tubule‐interstitial nephritis in 6 patients. In‐hospital mortality was 29.7%. Overall, 39% regained serum creatinine in the normal range at 3 months, 36.7% died, 14.1% reached chronic kidney disease (CKD), 7.8% lost to follow‐up, and 2.3% had reached end‐stage renal disease.Conclusion: The majority of AKI‐D at our center was CAAKI. A significant chunk of AKI‐D (68.7%) was caused by preventable causes like toxins, sepsis, and AGE. Dysregulation of mineral metabolism was conspicuous. In chemical toxin vs. biological toxins and undifferentiated sepsis vs. the identifiable cause of sepsis, formers had significantly more in‐hospital mortality than the latter ones. AKI‐D is associated with high in‐hospital mortality, total mortality, and risk of progression to CKD at 3 months.


  • Open Access

    The Indian Chronic Kidney Disease (ICKD) study: baseline characteristics

    by Vivek Kumar, Ashok Kumar Yadav, Jasmine Sethi, Arpita Ghosh, Manisha Sahay, Narayan Prasad, Santosh Varughese, Sreejith Parameswaran, Natarajan Gopalakrishnan, Prabhjot Kaur, et al.

    Chronic kidney disease (CKD) is an important cause of morbidity and mortality worldwide. There is a lack of information on epidemiology and progression of CKD in low–middle income countries. The Indian Chronic Kidney Disease (ICKD) study aims to identify factors that associate with CKD progression, and development of kidney failure and cardiovascular disease (CVD) in Indian patients with CKD. ICKD study is prospective, multicentric cohort study enrolling patients with estimated glomerular filtration rate (eGFR) 15–60 mL/min/1.73 m2, or >60 mL/min/1.73 m2 with proteinuria. Clinical details and biological samples are collected at annual visits. We analysed the baseline characteristics including socio-demographic details, risk factors, disease characteristics and laboratory measurements. In addition, we compared characteristics between urban and rural participants. A total of 4056 patients have been enrolled up to 31 March 2020. The mean ± SD age was 50.3 ± 11.8 years, 67.2% were males, two-thirds of patients lived in rural areas and the median eGFR was 40 mL/min/1.73 m2. About 87% were hypertensive, 37% had diabetes, 22% had CVD, 6.7% had past history of acute kidney injury and 23% reported prior use of alternative drugs. Diabetic kidney disease, chronic interstitial nephritis (CIN) and CKD-cause unknown (CKDu) were the leading causes. Rural participants had more occupational exposure and tobacco use but lower educational status and income. CIN and unknown categories were leading causes in rural participants. The ICKD study is the only large cohort study of patients with mild-to-moderate CKD in a lower middle income country. Baseline characteristics of study population reveal differences as compared with other cohorts from high-income countries.


  • Open Access

    POS-578 SHORT TERM OUTCOMES OF TUNNELED CUFFED CATHETERS- A SINGLE CENTER EXPERIENCE

    by A. Jaryal, S. Vikrant, R. Singh, N. Chauhan, D. Sharma, A. Kumar


  • Open Access

    Fosfomycin for post-renal transplant urinary tract infection: Re-emergence of an old drug - a Case report

    by Sanjay Vikrant, Ajay Jaryal

    Urinary tract infection (UTI) is a common problem in renal transplant recipients (RTR). It is challenging to treat UTI in RTR, as they are immunosuppressed, prone to allograft dysfunction, and can have adverse drug interactions due to the concomitant use of other immunosuppressant drugs. The UTI in RTR may present as asymptomatic bacteriuria (ASB), cystitis, pyelonephritis, or asymptomatic allograft dysfunction. Many times, UTI is caused by drug-resistant organisms, making it difficult to treat and also limiting the choice of empirical and specific antimicrobial therapy. Besides this, the treatment of ASB is controversial in RTR. Fosfomycin is an old drug which is re-emerging as an empirical antibiotic for UTI. Herein, we report a patient with multidrug-resistant ASB, within 1st month of transplant treated successfully with a single dose of fosfomycin.

  • Lentiform fork sign: Uremia alone or multifactorial causation?

    by Ajay Jaryal, Suresh Thakur, Joginder Singh Pathania, Sanjay Vikrant, Dinesh Kumar, Lokesh Verma

    Neurological complications are common in patients with acute or chronic renal failure, especially when there is marked reduction in the glomerular filtration rate (GFR). One such clinical syndrome, uremic encephalopathy (UE), occurs due to widespread dysfunction of central nervous system (CNS). It manifests with myriad clinical features and usually is suggested by bedside elicitation of asterixis (flapping tremor). Symptomatic involvement of the basal ganglia manifesting as choreoathetosis and clinical and radiological resolution with hemodialysis has been reported in the medical literature, but only rarely. The present report details such a case.


  • Open Access

    Etiological spectrum of anemia in non-dialysis-dependent chronic kidney disease: A single-center study from India

    by Sanjay Vikrant

    A retrospective study was conducted over seven years and it aimed to find out various causes of anemia among patients with chronic kidney disease (CKD). The study included nondialysis-dependent adult CKD patients who underwent anemia evaluation. A total of 584 patients were studied. Three hundred and twenty-one (55%) patients were male and 263 (45%) were female. The mean age of the patients was 55.5 ± 14 years. One hundred and seventy-eight (30.5%) had a diabetic CKD and 406 (69.5%) had a nondiabetic CKD. Seventy-two (12.3%) patients were in CKD Stage 3, 193 (33%) patients in CKD Stage 4, and 319 (54.6%) patients in CKD Stage 5. The mean hemoglobin was 9.2 ± 2.2 g/dL. There was a progressive fall in hemoglobin with increasing severity of CKD and in CKD Stage 3, 4, and 5 the mean hemoglobin was 10 ± 2.2, 9.4 ± 2.1, and 8.4 ± 1.9 g/dL, respectively (P = 0.001). Most (47.4%) patients had moderate anemia followed by anemia of mild (31.4%) and severe (21.4%) degrees. Three hundred and seven (52.6%) patients had percent transferrin saturation (TSAT) 12. A high proportion (74.6%) of patients with normocytic anemia had iron deficiency. In the majority of nondialysis-dependent CKD patients, the etiology of anemia may be multifactorial; therefore, the treatment should be determined by documented causes of anemia.